Clinical Trials Study
Copyright ©The Author(s) 2018.
World J Gastroenterol. Feb 28, 2018; 24(8): 941-948
Published online Feb 28, 2018. doi: 10.3748/wjg.v24.i8.941
Figure 1
Figure 1 Study design. 1Adverse reactions included leukopenia (white blood cell count < 3.5 × 109/L or neutrophils < 1.5 × 109/L), hepatoxicity, severe gastrointestinal adverse reactions and severe hair loss; 2Drug dose was increased by 0.5 mg/kg daily every month gradually to 1.0-2.0 mg/kg daily. AZA: Azathioprine; IBD: Inflammatory bowel disease.